Re: Lilly Stock Spirals Down (Time for a little celebration!)

[Guest guest]

>I had lunch and some calcium/magnesium and feeling

>much better now

>A walk and some sleep will do me good tonight.

While working at the health food store i learned that

we really shouldn't be taking calcium. It was added to

*most all* food you buy in the grocery stores. It

*must* be balanced 2 to 1 ratio with magnisum.

Otherwise it creates what looks like osteorporisis

(sp) or arthritus. etc. Yea, what looks like a calcium

defficiencly is *really* a magnisum deficiency. So

what i'm saying is to take magnisum to balance it

with the calcium you are getting in your foods out of

the grocery store. Think about that one and let me

know what you come up with. Without this balance, to

much calcium can become a toxin.

Connie

Re: Lilly Stock

Spirals

> > > Down (Time for a little

> > > > celebration!)

> > > >

> > > >

> > > > >

> > > > > I hate for people to lose jobs but I love

this

> > > news. goes to show

> > > > > what unethical and harmful products will get

a

> > > business everytime.

> > > > > Couldn't happen to a better bunch. Makes me

think

> > > carefully about

> > > > > where I will work.

> > > > >

> > > > >

> > > > >

> > > > >

> > > > >

> > > > > >

> > > > > >

> > > > > >

> > >

http://www.indystar.com/articles/3/189440-8983-223.html

> > > > > >

> > > > > > Lilly stock spirals down

> > > > > > The Indianapolis company's share price has

hit a

> > > 52-week low every day

> > > > > since

> > > > > > Oct. 19.

> > > > > >

> > > > > > By J.K. Wall

> > > > > > jk.wall@...

> > > > > > October 26, 2004

> > > > > >

> > > > > > Eli Lilly and Co. shares hit another

52-week low

> > > Monday as the company

> > > > > > continued to feel the fallout from its own

weak

> > > financial growth and

> > > > that

> > > > > of

> > > > > > the whole pharmaceutical industry.

> > > > > >

> > > > > > Shares of the Indianapolis-based company

have

> > > fallen nearly 15 percent

> > > > in

> > > > > > the past two weeks, closing Monday at

$50.44 a

> > > share. The value has

> > > > fallen

> > > > > > by more than 28 percent since Jan. 1.

Lilly

> > > stock closed as high as

> > > > $76.95

> > > > > > in early June.

> > > > > >

> > > > > > The share price has hit a new 52-week low

every

> > > day since Oct. 19.

> > > > Lilly,

> > > > > > Central Indiana's largest private

employer, last

> > > week announced job

> > > cuts

> > > > > and

> > > > > > reported sales that disappointed Wall

Street

> > > analysts.

> > > > > >

> > > > > > If the difficulties at Lilly are

prolonged, they

> > > could indirectly

> > > affect

> > > > > the

> > > > > > Lilly Endowment, a massive Indianapolis

> > > philanthropic foundation.

> > > > > >

> > > > > > While the $10.8 billion endowment is

independent

> > > of the drug maker,

> > > > Lilly

> > > > > > stock is the endowment's most significant

asset.

> > > > > >

> > > > > > For now, however, the company's

performance

> > > should not change the

> > > > > > endowment's level of giving, said an

official

> > > with the Indiana

> > > > Grantmakers

> > > > > > Alliance.

> > > > > >

> > > > > > " Private foundations are obligated to pay

out at

> > > least 5 percent of

> > > > their

> > > > > > assets. However, the 5 percent is based on

a

> > > three-year rolling

> > > > average, "

> > > > > > said Audette, vice president of

the

> > > alliance, in a written

> > > > > > statement. " Therefore a spike one way or

the

> > > other in the market or in

> > > a

> > > > > > particular stock, even if a foundation is

heavy

> > > in that stock, has

> > > > little

> > > > > > effect on the long-term giving. "

> > > > > > Other drug companies also aren't faring

well on

> > > Wall Street.

> > > > > >

> > > > > > Last week was the fifth straight that the

> > > American Stock Exchange

> > > > > > Pharmaceutical Index fell. The slide

started

> > > just before Merck & Co

> > > Inc.

> > > > > > announced that it would yank Vioxx, a

popular

> > > arthritis drug, from the

> > > > > > market. Hazlett, a pharmaceuticals

> > > analyst at SunTrust

> > > > > > Humphrey, described that development as a

> > > " disaster " for Merck that

> > > has

> > > > > > affected the entire industry.

> > > > > >

> > > > > > Pfizer, the world's largest drug maker,

> > > disappointed investors last

> > > week

> > > > > > with revenues that missed analysts'

estimates.

> > > Its profits beat

> > > > estimates

> > > > > by

> > > > > > a penny per share, but it also warned that

next

> > > year's results could

> > > be

> > > > > hurt

> > > > > > by the arrival of generic competitors

against

> > > four of its drugs.

> > > > > > GlaxoKline, which reports earnings

> > > Thursday, faces several

> > > cheaper

> > > > > > copycat medications that will compete with

its

> > > compounds.

> > > > > >

> > > > > > In addition, Hazlett said, pharmaceutical

> > > companies also fear that a

> > > > > victory

> > > > > > by presidential candidate Kerry would

lead

> > > to lower drug prices

> > > and

> > > > > > imported drugs from Canada. Kerry has said

he

> > > wants government health

> > > > care

> > > > > > programs to negotiate lower prices with

drug

> > > companies.

> > > > > >

> > > > > > " The specter of a Democratic

administration has

> > > had some effect on the

> > > > > > stocks, " Hazlett said.

> > > > > > Politics aside, Lilly has struggled to

keep

> > > sales up and costs down.

> > > > > >

> > > > > > In the past two weeks, Lilly has announced

it

> > > would cut 1,000 jobs

> > > from

> > > > > its

> > > > > > work force, which numbers 46,000

worldwide.

> > > Lilly's operations in

> > > > > > Indianapolis will absorb 225. Lilly also

> > > instituted a hiring freeze in

> > > > > > August.

> > > > > >

> > > > > > Those cost-cutting moves helped Lilly post

a 6

> > > percent increase in

> > > > profits

> > > > > > in its fiscal third quarter; revenue grew

a

> > > modest 4 percent, leaving

> > > > Wall

> > > > > > Street nonplussed.

> > > > > >

> > > > > > " The good news is management had the

'wiggle

> > > room' -- the bad news is

> > > > they

> > > > > > needed it (and likely will continue to), "

wrote

> > > Carl Seiden, an

> > > analyst

> > > > > > covering Lilly for the brokerage firm UBS.

> > > > > >

> > > > > > Many analysts are worried by declining

sales of

> > > Lilly's blockbuster

> > > > drug,

> > > > > > Zyprexa. It generates more than $4 billion

a

> > > year for Lilly, and, by

> > > > some

> > > > > > analysts' estimates, accounts for 60

percent of

> > > the company's profits.

> > > > > >

> > > > > > Sales of the antipsychotic drug fell 9

percent

> > > in Lilly's third

> > > quarter,

> > > > > > including a 22 percent drop in the United

> > > States. And the patent

> > > > challenge

> > > > > > brought against Zyprexa by a generic drug

maker,

> > > which is now in the

> > > > hands

> > > > > > of an Indianapolis judge, still hangs like

a

> > > cloud over Lilly.

> > > > > >

> > > > > > " We believe investors are better off on

the

> > > sidelines until the

> > > > visibility

> > > > > > on the Zyprexa controversies improve, "

Seiden

> > > wrote.

> > > > > >

> > > > > > Other analysts have been disappointed in

early

> > > sales of Lilly's newest

> > > > > > drugs, such as Strattera, which is used in

> > > treating attention-deficit

> > > > > > hyperactivity disorder.

> > > > > >

> > > > > > But Hazlett takes a rosier view on Lilly.

He

> > > points to Cymbalta, an

> > > > > > antidepressant Lilly rolled out this

summer, as

> > > evidence for his

> > > > > prediction

> > > > > > of strong profit growth the next two

years.

> > > > > >

> > > > > > Hazlett wrote that he " would recommend

that

> > > investors use the recent

> > > > > > weakness to establish or add to a

position. "

> > > > > >

> > > > > > Star reporter O'Neal contributed to

this

> > > story.

> > > > > > Call Star reporter J.K. Wall at (317)

444-6287.

> > > > > >

> > > > > >

> > > > > >

> > > > > >

> > > > > >

> > > > > >

> > > > > >

[Guest guest]

Hello Jim and all,

Wish I could be here more and join in all the fun!

Here's a cleaned up version for y'all!

Best to all,

Cassandra Dawn

===============

===============

http://www.indystar.com/articles/3/189440-8983-223.html

Lilly stock spirals down

The Indianapolis company's share price has hit a 52-week low every

day since Oct. 19.

By J.K. Wall

jk.wall@...

October 26, 2004

Eli Lilly and Co. shares hit another 52-week low Monday as the

company continued to feel the fallout from its own weak financial

growth and that of the whole pharmaceutical industry.

Shares of the Indianapolis-based company have fallen nearly 15

percent in the past two weeks, closing Monday at $50.44 a share. The

value has fallen by more than 28 percent since Jan. 1. Lilly stock

closed as high as $76.95 in early June.

The share price has hit a new 52-week low every day since Oct. 19.

Lilly, Central Indiana's largest private employer, last week

announced job cuts and reported sales that disappointed Wall Street

analysts.

If the difficulties at Lilly are prolonged, they could indirectly

affect the Lilly Endowment, a massive Indianapolis philanthropic

foundation.

While the $10.8 billion endowment is independent of the drug maker,

Lilly stock is the endowment's most significant asset.

For now, however, the company's performance should not change the

endowment's level of giving, said an official with the Indiana

Grantmakers Alliance.

" Private foundations are obligated to pay out at least 5 percent of

their assets. However, the 5 percent is based on a three-year

rolling average, " said Audette, vice president of the

alliance, in a written statement. " Therefore a spike one way or the

other in the market or in a particular stock, even if a foundation

is heavy in that stock, has little effect on the long-term giving. "

Other drug companies also aren't faring well on Wall Street.

Last week was the fifth straight that the American Stock Exchange

Pharmaceutical Index fell. The slide started just before Merck & Co

Inc. announced that it would yank Vioxx, a popular arthritis drug,

from the market. Hazlett, a pharmaceuticals analyst at

SunTrust Humphrey, described that development as

a " disaster " for Merck that has affected the entire industry.

Pfizer, the world's largest drug maker, disappointed investors last

week with revenues that missed analysts' estimates. Its profits beat

estimates by a penny per share, but it also warned that next year's

results could be hurt by the arrival of generic competitors against

four of its drugs.

GlaxoKline, which reports earnings Thursday, faces several

cheaper copycat medications that will compete with its compounds.

In addition, Hazlett said, pharmaceutical companies also fear that a

victory by presidential candidate Kerry would lead to lower

drug prices and imported drugs from Canada. Kerry has said he wants

government health care programs to negotiate lower prices with drug

companies.

" The specter of a Democratic administration has had some effect on

the stocks, " Hazlett said.

Politics aside, Lilly has struggled to keep sales up and costs down.

In the past two weeks, Lilly has announced it would cut 1,000 jobs

from its work force, which numbers 46,000 worldwide. Lilly's

operations in Indianapolis will absorb 225. Lilly also instituted a

hiring freeze in August.

Those cost-cutting moves helped Lilly post a 6 percent increase in

profits in its fiscal third quarter; revenue grew a modest 4

percent, leaving Wall Street nonplussed.

" The good news is management had the 'wiggle room' -- the bad news

is they needed it (and likely will continue to), " wrote Carl Seiden,

an analyst covering Lilly for the brokerage firm UBS.

Many analysts are worried by declining sales of Lilly's blockbuster

drug, Zyprexa. It generates more than $4 billion a year for Lilly,

and, by some analysts' estimates, accounts for 60 percent of the

company's profits.

Sales of the antipsychotic drug fell 9 percent in Lilly's third

quarter, including a 22 percent drop in the United States. And the

patent challenge brought against Zyprexa by a generic drug maker,

which is now in the hands of an Indianapolis judge, still hangs like

a cloud over Lilly.

" We believe investors are better off on the sidelines until the

visibility on the Zyprexa controversies improve, " Seiden wrote.

Other analysts have been disappointed in early sales of Lilly's

newest drugs, such as Strattera, which is used in treating attention-

deficit hyperactivity disorder.

But Hazlett takes a rosier view on Lilly. He points to Cymbalta, an

antidepressant Lilly rolled out this summer, as evidence for his

prediction of strong profit growth the next two years.

Hazlett wrote that he " would recommend that investors use the recent

weakness to establish or add to a position. "

Star reporter O'Neal contributed to this story.

Call Star reporter J.K. Wall at (317) 444-6287.

======================

I hate for people to lose jobs but I love this news. goes to show

what unethical and harmful products will get a business everytime.

Couldn't happen to a better bunch. Makes me think carefully about

where I will work.

[Guest guest]

Hello Jim and all,

Wish I could be here more and join in all the fun!

Here's a cleaned up version for y'all!

Best to all,

Cassandra Dawn

===============

===============

http://www.indystar.com/articles/3/189440-8983-223.html

Lilly stock spirals down

The Indianapolis company's share price has hit a 52-week low every

day since Oct. 19.

By J.K. Wall

jk.wall@...

October 26, 2004

Eli Lilly and Co. shares hit another 52-week low Monday as the

company continued to feel the fallout from its own weak financial

growth and that of the whole pharmaceutical industry.

Shares of the Indianapolis-based company have fallen nearly 15

percent in the past two weeks, closing Monday at $50.44 a share. The

value has fallen by more than 28 percent since Jan. 1. Lilly stock

closed as high as $76.95 in early June.

The share price has hit a new 52-week low every day since Oct. 19.

Lilly, Central Indiana's largest private employer, last week

announced job cuts and reported sales that disappointed Wall Street

analysts.

If the difficulties at Lilly are prolonged, they could indirectly

affect the Lilly Endowment, a massive Indianapolis philanthropic

foundation.

While the $10.8 billion endowment is independent of the drug maker,

Lilly stock is the endowment's most significant asset.

For now, however, the company's performance should not change the

endowment's level of giving, said an official with the Indiana

Grantmakers Alliance.

" Private foundations are obligated to pay out at least 5 percent of

their assets. However, the 5 percent is based on a three-year

rolling average, " said Audette, vice president of the

alliance, in a written statement. " Therefore a spike one way or the

other in the market or in a particular stock, even if a foundation

is heavy in that stock, has little effect on the long-term giving. "

Other drug companies also aren't faring well on Wall Street.

Last week was the fifth straight that the American Stock Exchange

Pharmaceutical Index fell. The slide started just before Merck & Co

Inc. announced that it would yank Vioxx, a popular arthritis drug,

from the market. Hazlett, a pharmaceuticals analyst at

SunTrust Humphrey, described that development as

a " disaster " for Merck that has affected the entire industry.

Pfizer, the world's largest drug maker, disappointed investors last

week with revenues that missed analysts' estimates. Its profits beat

estimates by a penny per share, but it also warned that next year's

results could be hurt by the arrival of generic competitors against

four of its drugs.

GlaxoKline, which reports earnings Thursday, faces several

cheaper copycat medications that will compete with its compounds.

In addition, Hazlett said, pharmaceutical companies also fear that a

victory by presidential candidate Kerry would lead to lower

drug prices and imported drugs from Canada. Kerry has said he wants

government health care programs to negotiate lower prices with drug

companies.

" The specter of a Democratic administration has had some effect on

the stocks, " Hazlett said.

Politics aside, Lilly has struggled to keep sales up and costs down.

In the past two weeks, Lilly has announced it would cut 1,000 jobs

from its work force, which numbers 46,000 worldwide. Lilly's

operations in Indianapolis will absorb 225. Lilly also instituted a

hiring freeze in August.

Those cost-cutting moves helped Lilly post a 6 percent increase in

profits in its fiscal third quarter; revenue grew a modest 4

percent, leaving Wall Street nonplussed.

" The good news is management had the 'wiggle room' -- the bad news

is they needed it (and likely will continue to), " wrote Carl Seiden,

an analyst covering Lilly for the brokerage firm UBS.

Many analysts are worried by declining sales of Lilly's blockbuster

drug, Zyprexa. It generates more than $4 billion a year for Lilly,

and, by some analysts' estimates, accounts for 60 percent of the

company's profits.

Sales of the antipsychotic drug fell 9 percent in Lilly's third

quarter, including a 22 percent drop in the United States. And the

patent challenge brought against Zyprexa by a generic drug maker,

which is now in the hands of an Indianapolis judge, still hangs like

a cloud over Lilly.

" We believe investors are better off on the sidelines until the

visibility on the Zyprexa controversies improve, " Seiden wrote.

Other analysts have been disappointed in early sales of Lilly's

newest drugs, such as Strattera, which is used in treating attention-

deficit hyperactivity disorder.

But Hazlett takes a rosier view on Lilly. He points to Cymbalta, an

antidepressant Lilly rolled out this summer, as evidence for his

prediction of strong profit growth the next two years.

Hazlett wrote that he " would recommend that investors use the recent

weakness to establish or add to a position. "

Star reporter O'Neal contributed to this story.

Call Star reporter J.K. Wall at (317) 444-6287.

======================

I hate for people to lose jobs but I love this news. goes to show

what unethical and harmful products will get a business everytime.

Couldn't happen to a better bunch. Makes me think carefully about

where I will work.

[Guest guest]

Connie,

I agree totally. I take AtoB Calm but there are others

the thing to know is that there has to be acid, like vinegar

to get them work properly

Jim

Re: Lilly Stock

> Spirals

> > > > Down (Time for a little

> > > > > celebration!)

> > > > >

> > > > >

> > > > > >

> > > > > > I hate for people to lose jobs but I love

> this

> > > > news. goes to show

> > > > > > what unethical and harmful products will get

> a

> > > > business everytime.

> > > > > > Couldn't happen to a better bunch. Makes me

> think

> > > > carefully about

> > > > > > where I will work.

> > > > > >

> > > > > >

> > > > > >

> > > > > >

> > > > > >

> > > > > > >

> > > > > > >

> > > > > > >

> > > >

> http://www.indystar.com/articles/3/189440-8983-223.html

> > > > > > >

> > > > > > > Lilly stock spirals down

> > > > > > > The Indianapolis company's share price has

> hit a

> > > > 52-week low every day

> > > > > > since

> > > > > > > Oct. 19.

> > > > > > >

> > > > > > > By J.K. Wall

> > > > > > > jk.wall@...

> > > > > > > October 26, 2004

> > > > > > >

> > > > > > > Eli Lilly and Co. shares hit another

> 52-week low

> > > > Monday as the company

> > > > > > > continued to feel the fallout from its own

> weak

> > > > financial growth and

> > > > > that

> > > > > > of

> > > > > > > the whole pharmaceutical industry.

> > > > > > >

> > > > > > > Shares of the Indianapolis-based company

> have

> > > > fallen nearly 15 percent

> > > > > in

> > > > > > > the past two weeks, closing Monday at

> $50.44 a

> > > > share. The value has

> > > > > fallen

> > > > > > > by more than 28 percent since Jan. 1.

> Lilly

> > > > stock closed as high as

> > > > > $76.95

> > > > > > > in early June.

> > > > > > >

> > > > > > > The share price has hit a new 52-week low

> every

> > > > day since Oct. 19.

> > > > > Lilly,

> > > > > > > Central Indiana's largest private

> employer, last

> > > > week announced job

> > > > cuts

> > > > > > and

> > > > > > > reported sales that disappointed Wall

> Street

> > > > analysts.

> > > > > > >

> > > > > > > If the difficulties at Lilly are

> prolonged, they

> > > > could indirectly

> > > > affect

> > > > > > the

> > > > > > > Lilly Endowment, a massive Indianapolis

> > > > philanthropic foundation.

> > > > > > >

> > > > > > > While the $10.8 billion endowment is

> independent

> > > > of the drug maker,

> > > > > Lilly

> > > > > > > stock is the endowment's most significant

> asset.

> > > > > > >

> > > > > > > For now, however, the company's

> performance

> > > > should not change the

> > > > > > > endowment's level of giving, said an

> official

> > > > with the Indiana

> > > > > Grantmakers

> > > > > > > Alliance.

> > > > > > >

> > > > > > > " Private foundations are obligated to pay

> out at

> > > > least 5 percent of

> > > > > their

> > > > > > > assets. However, the 5 percent is based on

> a

> > > > three-year rolling

> > > > > average, "

> > > > > > > said Audette, vice president of

> the

> > > > alliance, in a written

> > > > > > > statement. " Therefore a spike one way or

> the

> > > > other in the market or in

> > > > a

> > > > > > > particular stock, even if a foundation is

> heavy

> > > > in that stock, has

> > > > > little

> > > > > > > effect on the long-term giving. "

> > > > > > > Other drug companies also aren't faring

> well on

> > > > Wall Street.

> > > > > > >

> > > > > > > Last week was the fifth straight that the

> > > > American Stock Exchange

> > > > > > > Pharmaceutical Index fell. The slide

> started

> > > > just before Merck & Co

> > > > Inc.

> > > > > > > announced that it would yank Vioxx, a

> popular

> > > > arthritis drug, from the

> > > > > > > market. Hazlett, a pharmaceuticals

> > > > analyst at SunTrust

> > > > > > > Humphrey, described that development as a

> > > > " disaster " for Merck that

> > > > has

> > > > > > > affected the entire industry.

> > > > > > >

> > > > > > > Pfizer, the world's largest drug maker,

> > > > disappointed investors last

> > > > week

> > > > > > > with revenues that missed analysts'

> estimates.

> > > > Its profits beat

> > > > > estimates

> > > > > > by

> > > > > > > a penny per share, but it also warned that

> next

> > > > year's results could

> > > > be

> > > > > > hurt

> > > > > > > by the arrival of generic competitors

> against

> > > > four of its drugs.

> > > > > > > GlaxoKline, which reports earnings

> > > > Thursday, faces several

> > > > cheaper

> > > > > > > copycat medications that will compete with

> its

> > > > compounds.

> > > > > > >

> > > > > > > In addition, Hazlett said, pharmaceutical

> > > > companies also fear that a

> > > > > > victory

> > > > > > > by presidential candidate Kerry would

> lead

> > > > to lower drug prices

> > > > and

> > > > > > > imported drugs from Canada. Kerry has said

> he

> > > > wants government health

> > > > > care

> > > > > > > programs to negotiate lower prices with

> drug

> > > > companies.

> > > > > > >

> > > > > > > " The specter of a Democratic

> administration has

> > > > had some effect on the

> > > > > > > stocks, " Hazlett said.

> > > > > > > Politics aside, Lilly has struggled to

> keep

> > > > sales up and costs down.

> > > > > > >

> > > > > > > In the past two weeks, Lilly has announced

> it

> > > > would cut 1,000 jobs

> > > > from

> > > > > > its

> > > > > > > work force, which numbers 46,000

> worldwide.

> > > > Lilly's operations in

> > > > > > > Indianapolis will absorb 225. Lilly also

> > > > instituted a hiring freeze in

> > > > > > > August.

> > > > > > >

> > > > > > > Those cost-cutting moves helped Lilly post

> a 6

> > > > percent increase in

> > > > > profits

> > > > > > > in its fiscal third quarter; revenue grew

> a

> > > > modest 4 percent, leaving

> > > > > Wall

> > > > > > > Street nonplussed.

> > > > > > >

> > > > > > > " The good news is management had the

> 'wiggle

> > > > room' -- the bad news is

> > > > > they

> > > > > > > needed it (and likely will continue to), "

> wrote

> > > > Carl Seiden, an

> > > > analyst

> > > > > > > covering Lilly for the brokerage firm UBS.

> > > > > > >

> > > > > > > Many analysts are worried by declining

> sales of

> > > > Lilly's blockbuster

> > > > > drug,

> > > > > > > Zyprexa. It generates more than $4 billion

> a

> > > > year for Lilly, and, by

> > > > > some

> > > > > > > analysts' estimates, accounts for 60

> percent of

> > > > the company's profits.

> > > > > > >

> > > > > > > Sales of the antipsychotic drug fell 9

> percent

> > > > in Lilly's third

> > > > quarter,

> > > > > > > including a 22 percent drop in the United

> > > > States. And the patent

> > > > > challenge

> > > > > > > brought against Zyprexa by a generic drug

> maker,

> > > > which is now in the

> > > > > hands

> > > > > > > of an Indianapolis judge, still hangs like

> a

> > > > cloud over Lilly.

> > > > > > >

> > > > > > > " We believe investors are better off on

> the

> > > > sidelines until the

> > > > > visibility

> > > > > > > on the Zyprexa controversies improve, "

> Seiden

> > > > wrote.

> > > > > > >

> > > > > > > Other analysts have been disappointed in

> early

> > > > sales of Lilly's newest

> > > > > > > drugs, such as Strattera, which is used in

> > > > treating attention-deficit

> > > > > > > hyperactivity disorder.

> > > > > > >

> > > > > > > But Hazlett takes a rosier view on Lilly.

> He

> > > > points to Cymbalta, an

> > > > > > > antidepressant Lilly rolled out this

> summer, as

> > > > evidence for his

> > > > > > prediction

> > > > > > > of strong profit growth the next two

> years.

> > > > > > >

> > > > > > > Hazlett wrote that he " would recommend

> that

> > > > investors use the recent

> > > > > > > weakness to establish or add to a

> position. "

> > > > > > >

> > > > > > > Star reporter O'Neal contributed to

> this

> > > > story.

> > > > > > > Call Star reporter J.K. Wall at (317)

> 444-6287.

> > > > > > >

> > > > > > >

> > > > > > >

> > > > > > >

> > > > > > >

> > > > > > >

> > > > > > >